Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
MSD Rolls Out Airwin and Welireg in Japan
MSD said on August 18 that it has released two newly approved therapies in Japan — Airwin (sotatercept) for pulmonary arterial hypertension (PAH) and Welireg (belzutifan) for tumors associated with von Hippel-Lindau (VHL) disease and advanced renal cell carcinoma (RCC).…
To read the full story
Related Article
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
- Welireg Expected to Preserve Organ Function in VHL Disease: Urologist
September 11, 2025
- A “50-Billion-Yen Plus” Newcomer
September 4, 2025
- Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
September 3, 2025
- Welireg, Airwin, Talvey and More Set for NHI Listing; Premiums Wiped Out by “Zero” Rule
August 7, 2025
BUSINESS
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
- Lasker Win “Not the Finish Line” for Chugai Researchers; Next-Gen Drug Advances
September 11, 2026
- Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
September 11, 2026
- Silchester Emerges as Suzuken’s Top Shareholder with 10.03% Voting Stake
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…